Access to medicines after TRIPS: Is compulsory licensing an effective mechanism to lower drug prices? A review of the existing evidence
Tóm tắt
While Trade-Related Aspects of Intellectual Property Rights (TRIPS) was expected to hike up prices of patented medicines, there was no consensus on its likely final impact on access, because the agreement housed instruments to address this challenge. For instance, compulsory licensing, through the facilitation of price reductions, was considered to be an important countermeasure. However, little is known about the extent to which compulsory licensing has actually been effective in reducing prices of much-needed patented drugs. To fill this gap, this paper undertakes a systematic-review of the existing evidence on the impact of compulsory licensing on drug prices. Retrieval and analysis of 51 observations of pre- and post-compulsory licensing prices indicate that a compulsory licensing event is likely to reduce the price of a patented drug, albeit with some caveats. Moreover, compulsory licensing procurement from the international market is likely to be more effective in reducing drug prices than contracts to local companies. These findings are reconfirmed in the race to improve access to Remdesivir for hospitalized COVID-19 patients. Clearly, the future incidence and impact of compulsory licensing will depend on further possible procedural refinements to ease its implementation, the development of technological and manufacturing capabilities in developing countries, and the importance of biologics among life-saving drugs.
Tài liệu tham khảo
Amin, T., & Kesselheim, A. S. 2012. Secondary patenting of branded pharmaceuticals: A case study of how patents on two HIV drugs could be extended for decades. Health Affairs, 31(10): 2286–2294. https://doi.org/10.1377/hlthaff.2012.0107.
Babovic, S., & Wasan, K. M. 2011. Impact of the trade-related aspects of intellectual property rights (TRIPS) agreement on India as a supplier of generic antiretrovirals. Journal of Pharmaceutical Sciences, 100(3): 816–821. https://doi.org/10.1002/jps.22326.
Baker, B. 2020. Gilead remdesivir licenses: Half measures are not nearly good enough. Health GAP (Global Access Project). https://healthgap.org/gilead-remdesivir-licenses-half-measures-are-not-nearly-good-enough/.
Beall, R. F., & Kuhn, R. 2012. Trends in compulsory licensing of pharmaceuticals since the doha declaration: A database analysis. PLoS Medicine, 9(1): e1001154. https://doi.org/10.1371/journal.pmed.1001154.
Beall, R. F., Kuhn, R., & Attaran, A. 2015. Compulsory licensing often did not produce lower prices for antiretrovirals compared to international procurement. Health Affairs, 34(3): 493–501.
Bognar, C. L. F. B., Bychkovsky, B. L., & de Lopes, G. D. 2016. Compulsory licenses for cancer drugs: Does circumventing patent rights improve access to oncology medications? Journal of Global Oncology, 2(5): 292–301. https://doi.org/10.1200/JGO.2016.005363.
Boseley, S. 2020. US secures world stock of key Covid-19 drug remdesivir. The Guardian. https://www.theguardian.com/us-news/2020/jun/30/us-buys-up-world-stock-of-key-covid-19-drug.
Boulet, P., Perriens, J., Renaud-Théry, F., & Velasquez, G. 2000. Pharmaceuticals and the WTO TRIPS Agreement: Questions and Answers. UNAIDS/WHO. http://apps.who.int/medicinedocs/pdf/whozip18e/whozip18e.pdf.
Cappuyns, P., & Vanherpe, J. 2018. The Scoop from Europe: A Licence! And Quick! Recent Developments Concerning Compulsory Licences for Patented Pharmaceuticals in the European Union.
Chakrabarti, G. 2015. Impact and significance of compulsory licensing for access to medicine. International Journal of Intellectual Property Management, 8(3/4): 172. https://doi.org/10.1504/IJIPM.2015.076542.
Chami, G., & Wasswa-Kintu, S. 2011. Compulsory licensing of generic drugs remains mired in quagmires. Canadian Medical Association Journal, 183(11): E705–E706. https://doi.org/10.1503/cmaj.109-3898.
Chaudhuri, S., Park, C., & Gopakumar, K. M. 2010. Five years into the product patent regime: India’s response. United Nations Development Programme (UNDP). https://www.undp.org/content/dam/india/docs/five_years_into_the_product_patent_regime_india%e2%80%99s_response.pdf.
Chung, J. 2017. Special issue on therapeutic antibodies and biopharmaceuticals. Experimental & Molecular Medicine, 49(3): e304. https://doi.org/10.1038/emm.2017.46.
Correa, C. M. 2006. Pharmaceutical inventions: When is the granting of a patent justified? International Journal of Intellectual Property Management, 1(1): 4–21.
Diependaele, L., Cockbain, J., & Sterckx, S. 2018. Similar or the same? Why biosimilars are not the solution. The Journal of Law, Medicine & Ethics, 46(3): 776–790. https://doi.org/10.1177/1073110518804241.
Dowlat, H. A., Kuhlmann, M. K., Khatami, H., & Ampudia-Blasco, F. J. 2016. Interchangeability among reference insulin analogues and their biosimilars: Regulatory framework, study design and clinical implications. Diabetes, Obesity & Metabolism, 18(8): 737–746. https://doi.org/10.1111/dom.12676.
Ecks, S. 2008. Global pharmaceutical markets and corporate citizenship: The case of Novartis’ anti-cancer drug Glivec. BioSocieties, 3(2): 165–181.
Ford, N., Wilson, D., Chaves, G. C., Lotrowska, M., & Kijtiwatchakul, K. 2007. Sustaining access to antiretroviral therapy in the less-developed world: Lessons from Brazil and Thailand. AIDS, 21(Suppl 4): S21–S29. https://doi.org/10.1097/01.aids.0000279703.78685.a6.
Gehl Sampath, P. 2005. Economic aspects of access to medicines after 2005: Product patent protection and emerging firm strategies in the Indian pharmaceutical industry. http://wwwlive.who.int/entity/intellectualproperty/studies/PadmashreeSampathFinal.pdf.
Gervais, D. J. 2003. The TRIPS agreement: Drafting history and analysis. London: Sweet & Maxwell.
Gold, E. R., & Morin, J.-F. 2012. Promising trends in access to medicines. Global Policy, 3(2): 231–237. https://doi.org/10.1111/j.1758-5899.2011.00110.x.
Guennif, S., & Ramani, S. V. 2012. Explaining divergence in catching-up in pharma between India and Brazil using the NSI framework. Research Policy, 41(2): 430–441. https://doi.org/10.1016/j.respol.2011.09.005.
Hannah, E. N. 2011. NGOs and the European Union: Examining the power of epistemes in the EC’s TRIPS and access to medicines negotiations. Journal of Civil Society, 7(2): 179–206. https://doi.org/10.1080/17448689.2011.573669.
Hason, A. K., & Shimotake, J. E. 2006. Recent developments in Patent Rights for Pharmaceuticals in China and India Global Interdependence and International Commercial Law: International Law Students Association: Fall Conference 2005. Pace International Law Review, 18(1): 303–316.
Houldsworth, A. 2020. The key covid-19 compulsory licensing developments so far|IAM. IAM Media. https://www.iam-media.com/coronavirus/the-key-covid-19-compulsory-licensing-developments-so-far.
Jesson, J., Matheson, L., & Lacey, F. M. 2011. Doing your literature review: Traditional and systematic techniques. Thousand Oaks: Sage.
Kale, D., & Little, S. 2007. From imitation to innovation: The evolution of R&D capabilities and learning processes in the indian pharmaceutical industry. Technology Analysis & Strategic Management, 19(5): 589–609. https://doi.org/10.1080/09537320701521317.
Konde, V. 2016. Recent developments in compulsory licensing of pharmaceutical patents in India. Journal of Commercial Biotechnology. https://doi.org/10.5912/jcb733.
Loi n°2020-290 d’urgence pour faire face à l’épidémie de covid-19, Loi n°2020-290, NOR: PRMX2007883Z. 2020. https://www.senat.fr/application-des-lois/pjl19-376.html.
Love, J. P. 2007. Recent examples of the use of compulsory licenses on patents. Knowledge Ecology International, 8.
Luca, C. D. 2015. Medicine patent pool—pharma philanthropy or PR? Expert Opinion on Therapeutic Patents, 25(11): 1223–1227. https://doi.org/10.1517/13543776.2015.1075004.
Manu, T. 2015. Building national initiatives of compulsory licences: Reflecting on the Indian jurisprudence as a model for developing countries. Journal of International Trade Law and Policy. https://doi.org/10.1108/JITLP-07-2014-0015.
Medicines Law & Policy. 2017. Flow chart tools for TRIPS flexibilities. https://medicineslawandpolicy.org/wp-content/uploads/2017/05/Flowchart-Tools-MLP.pdf.
Medicines Law & Policy. 2020. COVID-19 Technology Access Pool (C-TAP): A promising human rights approach. https://medicineslawandpolicy.org/2020/06/covid-19-technology-access-pool-c-tap-a-promising-human-rights-approach/.
Mohara, A., Yamabhai, I., Chaisiri, K., Tantivess, S., & Teerawattananon, Y. 2012. Impact of the introduction of government use licenses on the drug expenditure on seven medicines in Thailand. Value in Health, 15(1): S95–S99. https://doi.org/10.1016/j.jval.2011.11.016.
OECD. 2020. Treatments and a vaccine for COVID-19: The need for coordinating policies on R&D, manufacturing and access (OECD Policy Responses to Coronavirus (COVID-19)). Organisation for Economic Co-operation and Development. https://www.oecd.org/coronavirus/policy-responses/treatments-and-a-vaccine-for-covid-19-the-need-for-coordinating-policies-on-r-d-manufacturing-and-access-6e7669a9/.
Oh, C. 2006. Compulsory licences: Recent experiences in developing countries. International Journal of Intellectual Property Management, 1(1/2): 22. https://doi.org/10.1504/IJIPM.2006.011020.
Ooms, G., & Hanefeld, J. 2019. Threat of compulsory licences could increase access to essential medicines. BMJ. https://doi.org/10.1136/bmj.l2098.
Petticrew, M., & Roberts, H. 2008. Systematic reviews in the social sciences: A practical guide. New York: Wiley.
Prasad, V., & Babu, P. S. S. K. 2013. Compulsory licensing: Implications on multinational drug companies. International Journal of Intellectual Property Management, 6(4): 247. https://doi.org/10.1504/IJIPM.2013.057621.
Rajkumar, R., & Kesselheim, A. S. 2013. Balancing access and innovation: India’s supreme court rules on imatinib. JAMA, 310(3): 263–264. https://doi.org/10.1001/jama.2013.7336.
Raju, K. D. 2017. Compulsory v voluntary licensing: A legitimate way to enhance access to essential medicines in developing countries. Journal of Intellectual Property Rights. Scopus. https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018280228&partnerID=40&md5=3d276f5bcd26b1d9e6bfc6cda929d0c6.
Ramani, S. V., & Mukherjee, V. 2014. Can breakthrough innovations serve the poor (bop) and create reputational (CSR) value? Indian case studies. Technovation, 34(5–6): 295–305.
Ramani, S. V., & Urias, E. 2015. Access to critical medicines: When are compulsory licenses effective in price negotiations? Social Science and Medicine, 135: 75–83. https://doi.org/10.1016/j.socscimed.2015.04.023.
Ramani, S. V., & Urias, E. 2018. When access to drugs meets catch-up: Insights from the use of CL threats to improve access to ARV drugs in Brazil. Research Policy, 47(8): 1538–1552. https://doi.org/10.1016/j.respol.2018.05.008.
Rees, V. 2020. Mylan partners with Gilead to expand access to remdesivir. European Pharmaceutical Review. https://www.europeanpharmaceuticalreview.com/news/119469/mylan-partners-with-gilead-to-manufacture-remdesivir-potential-covid-19-treatment/.
Rodrigues, W. C. V., & Soler, O. 2009. Compulsory licensing of efavirenz in Brazil in 2007: Contextualization. Revista Panamericana de Salud Pública, 26(6): 553–559. https://doi.org/10.1590/S1020-49892009001200012.
Sanders, B. 2005. https://www.sanders.senate.gov/download/051215-letter/?inline=file.
Saroha, S., Kaushik, D., & Nanda, A. 2015. Compulsory licensing of drug products in developing countries. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector, 12(3–4): 89–94. https://doi.org/10.1177/1741134313503827.
Scherer, F., & Watal, J. 2002. Post-TRIPS options for access to patented medicines in developing countries. Journal of International Economic Law, 5: 913–939.
Son, K.-B., & Lee, T.-J. 2018. Compulsory licensing of pharmaceuticals reconsidered: Current situation and implications for access to medicines. Global Public Health, 13(10): 1430–1440. https://doi.org/10.1080/17441692.2017.1407811.
Stirner, B., & Thangaraj, H. 2013. Learning from practice: Compulsory licensing cases and access to medicines. Pharmaceutical Patent Analyst, 2(2): 195–213. https://doi.org/10.4155/ppa.12.91.
’t Hoen, E. 2020a. Covid-19 and the comeback of compulsory licensing|Medicines Law & Policy. Medicines Law & Policy. https://medicineslawandpolicy.org/2020/03/covid-19-and-the-come-back-of-compulsory-licensing/.
’t Hoen, E. 2020b. Remdesivir developed country price announced. Medicines Law & Policy. https://medicineslawandpolicy.org/2020/06/remdesivir-developed-country-price-announced/.
’t Hoen, E., Berger, J., Calmy, A., & Moon, S. 2011. Driving a decade of change: HIV/AIDS, patents and access to medicines for all. Journal of the International AIDS Society, 14(1): 15. https://doi.org/10.1186/1758-2652-14-15.
Thanitcul, S., & Braslow, M. L. 2013. Compulsory licensing of chronic disease pharmaceuticals in Thailand. Thai Journal of Pharmaceutical Sciences, 37: 3.
Uman, L. S. 2011. Systematic reviews and meta-analyses. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 20(1): 57–59.
Urias, E. 2015. Improving access to HIV/AIDS treatment in Brazil: When are compulsory licenses effective in price negotiations? [Doctoral Dissertation, Maastricht University]. http://www.merit.unu.edu/training/theses/urias.pdf.
WTO. 2006. TRIPS and pharmaceutical patents: Obligations and exception. http://www.wto.org/english/tratop_e/trips_e/factsheet_pharm02_e.htm#art31.
WTO. 2015. WTO|2015 News items—WTO members agree to extend drug patent exemption for poorest members. https://www.wto.org/english/news_e/news15_e/trip_06nov15_e.htm.